Status: Recruiting
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Participants needed: 155
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: TORL Biotherapeutics, LLCUpdated: Jun 11, 2026Locations: 3
Eligibility criteria
Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A;... [+4]
T-cell lymphoma [+6]